Pharma RSS Digest - 2026-08-12
Overview
Today's pharma tape is light and dominated by company-specific catalysts rather than broad sector moves. A clinical milestone in ophthalmology from Kodiak Sciences and a healthcare-IT consolidation play from Kyndryl are the only items that cleared the bar for the lead section. The wider pipeline tape was thin enough that one notable financing round was set aside for insufficient context. In specialty therapeutics, retina and multiple sclerosis remain the two areas where near-term binary readouts could reshape positioning, while radiopharmaceuticals continue to post incremental safety and dosimetry data.
Key Developments
Kodiak Sciences initiates pivotal Phase 3 ALTO trial of KSI-501 in diabetic macular edema. The company has enrolled the first patients in ALTO, a multicenter, active-comparator-controlled study testing its IL-6/VEGF bispecific against aflibercept in roughly 910 patients. The trial is built around a superiority claim, with a primary visual-acuity endpoint averaged over Weeks 48–52 and a secondary diabetic retinopathy severity readout. It matters because many DME patients on anti-VEGF monotherapy still have residual edema and sub-optimal vision gains, and Kodiak is also using the program to test dosing intervals as long as 24 weeks, a potential differentiator on treatment burden. ALTO is the second registrational Phase 3 for KSI-501, running alongside DAYBREAK in wet AMD, making it a core value driver for a still precommercial company. Watch enrollment pace, any interim looks, and whether the readout schedule converges with DAYBREAK.
Kodiak Sciences clinical trial update
Kyndryl to acquire Healthcare IT Leaders to broaden AI-led healthcare modernization. Kyndryl announced an agreement to purchase Healthcare IT Leaders, a U.S.-focused enterprise IT consulting and application services firm for hospitals and health systems. The deal extends Kyndryl's footprint up the stack from infrastructure into clinical, operational, and workforce applications, letting it pitch as a single vendor across the healthcare IT environment. It reflects sustained pressure on providers and payors to modernize while preserving resiliency and compliance, and adds relationships with federal, academic, pediatric, and regional health systems. Financial terms were not disclosed and the deal is expected to close in the second quarter of Kyndryl's fiscal 2027, subject to regulatory review. Watch for pricing disclosure, integration milestones, and whether the combined entity lands marquee AI-modernization wins against competing systems integrators.
Watchlist
- Immunic board addition ahead of Phase 3 readout. Immunic appointed Elena Ridloff to its board, framing the move around the upcoming top-line Phase 3 ENSURE readout for vidofludimus calcium in relapsing multiple sclerosis, expected by year-end, and a planned confirmatory Phase 3 in progressive MS. The hire suggests preparation for potential regulatory filings and capital-raising tied to those milestones. [link]
- Oncoinvent publishes Radspherin dosimetry data. Normal-tissue dosimetry from nine Phase 1 patients with peritoneal metastases showed absorbed radiation to kidneys and red bone marrow well below toxicity thresholds, reinforcing Radspherin's safety profile and supporting continued development in ovarian and colorectal indications. [link]
- Radiopharmaceutical momentum continues to build incrementally. Beyond Oncoinvent, peer alpha-emitter programs face similar dosimetry constraints, so validated methods for estimating normal-tissue exposure could carry methodological weight beyond a single asset.